In the current trading session, NewAmsterdam Pharma Company NV’s (NAMS) stock is trading at the price of $31.84, a gain of 0.03% over last night’s close. So, the stock is trading at a price that is -24.19% less than its 52-week high of $42.00 and 126.46% better than its 52-week low of $14.06.
It is also essential to consider NAMS stock ratios like the price-to-sales ratio, which is 102.45 for the last year.NAMS’s price to book ratio for the most recent quarter was 4.95, resulting in an 5.13 price to cash per share for the period.
How does NewAmsterdam Pharma Company NV (NAMS) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1.
NewAmsterdam Pharma Company NV (NAMS): Earnings History
If we examine NewAmsterdam Pharma Company NV’s recent earnings history, in the last quarter ended on 9/30/2025, it posted adjusted earnings per share of -$0.53, beating the consensus of -$0.34. In other words, it beat the consensus by -$0.19, resulting in a -54.04% surprise. In the 3 months period before the previous quarter which was closed on 9/30/2025, the stock recorded adjusted earnings per share of -$0.53 in contrast with the Outlook of -$0.34. That was a difference of -$0.19 and a surprise of -54.04%.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Ownership Details
I will give a breakdown of the key shareholders in NewAmsterdam Pharma Company NV (NAMS). Recent figures show that the company’s insiders hold 0.47% of shares. A total of 219 institutional investors hold shares in the company, making 106.07% of its stock and 106.56% of its float.
Sep 30, 2025, it was reported that the Company’s largest institutional holder is Frazier Life Sciences Management, L.P. holding total of 16.7 shares that make 14.73% of the company’s total number of shares and are currently priced at 530.29 million.
The securities firm Bain Capital Life Sciences Investors, LLC holds 10.72 shares of NAMS, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 9.45%, and the holding percentage of shares is valued at 340.33 million.
